Associate Professor, Psychiatry-Massachusetts General Hospital, Harvard Medical School
Psychiatry
Dr. Oliver Freudenreich, MD
|
|
Give Review
Oliver Freudenreich, MD works in the field of Psychiatry. He went to medical school at UMDNJ-Robert Wood Johnson Medical School. He received 1 awards: "Super Doctor". Doctor Oliver Freudenreich, MD is also published. He has 101 publications published. The lastest publication: "Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.' He is registered with Medicare.
Publications
- Delineating responsibility: primary care provider perspective.
- Capable of More: Some Underemphasized Aspects of Capacity Assessment.
- A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in Schizophrenia patients: Effect on inflammation, psychopathology, cognition and l...
- Paliperidone depot is not different from haloperidol in relapse prevention of Schizophrenia, but different side effects should be considered.
- Discharges against medical advice.
- In reference to "Discharge against medical advice: How often do we intervene?".
- Characteristics of Homeless Adults with Serious Mental Illness Served by a State Mental Health Transitional Shelter.
- Horror diagnosticus psychiatricus - the fear of expanding nosologies and overdiagnosis in psychiatry.
- No Effect of Adjunctive, Repeated-Dose Intranasal Insulin Treatment on Psychopathology and Cognition in Patients With Schizophrenia.
- No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with Schizophrenia.
- Clozapine.
- Beyond Capacity: Identifying Ethical Dilemmas Underlying Capacity Evaluation Requests.
- Community psychiatry: what should future psychiatrists learn?
- Optimizing outcome with antipsychotic treatment in first-episode Schizophrenia: balancing efficacy and side effects.
- Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with Schizophrenia.
- How much haldol D does Larry really need?
- Clozapine decreases smoking in patients with chronic Schizophrenia.
- Haloperidol increases smoking in patients with Schizophrenia.
- Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics.
- Insight in Schizophrenia and mania.
- Monitoring of clozapine blood levels in the real world.
- Palinacousis after closed-head injury in a patient with Schizophrenia.
- Response of patients with treatment-refractory Schizophrenia to clozapine within three serum level ranges.
- Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.
- Smoking and therapeutic response to clozapine in patients with Schizophrenia.
- Zolpidem-related delirium: a case report.
- Anxiety and position-dependent neurologic findings due to autonomic dysreflexia.
- Colon perforation and peritonitis associated with clozapine.
- Schizophrenia.
- Exacerbation of idiopathic priapism with risperidone-citalopram Combination.
- Antipsychotic Combination therapy in schizophrenia. A review of efficacy and risks of current Combinations.
- Clinical experience with the management of Schizophrenia in the general hospital.
- The consultation psychiatrist as effective physician.
- Treatment noncompliance with orally disintegrating olanzapine tablets.
- Polypharmacy in Schizophrenia: a fuzzy concept.
- Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series.
- On biology, phenomenology, and pharmacology in Schizophrenia.
- Atypical laryngeal dystonia caused by an antiemetic.
- Two-year follow-up of a smoking cessation trial in patients with Schizophrenia: increased rates of smoking cessation and reduction.
- Checklist psychiatry's effect on psychiatric education.
- Focus on polypharmacy in Schizophrenia: does anyone truly benefit?
- Insight into current symptoms of Schizophrenia. Association with frontal cortical function and affect.
- Augmentation strategies in the treatment of Schizophrenia.
- Folate, homocysteine, and negative symptoms in Schizophrenia.
- A successful antipsychotic Combination trial. Quo Vadis?
- Attitudes of Schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
- A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in Schizophrenia patients.
- Medical morbidity and mortality in Schizophrenia: guidelines for psychiatrists.
- Added donepezil for stable Schizophrenia: a double-blind, placebo-controlled trial.
- A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
- A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in Schizophrenia.
- Drug-induced sialorrhea.
- Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
- Independent effects of tobacco abstinence and bupropion on cognitive function in Schizophrenia.
- The ABCs of suicide.
- Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic Schizophrenia.
- An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic Schizophrenia.
- The problem of the psychopharmacologist.
- Dietary intake profile of patients with Schizophrenia.
- Glucose metabolism in patients with Schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model anal...
- Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic Schizophrenia patients.
- Using a medical model with psychotic patients.
- Fronto-hippocampal function during temporal context monitoring in Schizophrenia.
- Stimulant misuse in college for "pseudo-attention deficit Disorder" during schizophrenia prodrome.
- Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with Schizophrenia.
- Catatonic coma with profound bradycardia.
- A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
- Risperidone augmentation for Schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.
- Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in Schizophrenia.
- The effects of transdermal nicotine on cognition in nonsmokers with Schizophrenia and nonpsychiatric controls.
- Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in Schizophrenia patients receiving atypical antipsychotics.
- A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in Schizophrenia.
- Resolution of late-onset hypomania after repair of carotid artery stenosis: a case of vascular hypomania.
- Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in Schizophrenia.
- Sexual functioning, psychopathology and quality of life in patients with Schizophrenia.
- A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in Schizophrenia.
- Hepatitis C in Schizophrenia: screening experience in a community-dwelling clozapine cohort.
- The evaluation and management of patients with first-episode Schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis.
- Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in Schizophrenia.
- High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with Schizophrenia.
- Posttraumatic stress Disorder, cognitive function and quality of life in patients with schizophrenia.
- Ownership, responsibility and hospital care: lessons for the consultation psychiatrist.
- Elevated clozapine serum level after treatment with amiodarone.
- Work-hour regulation: collateral damage to consultation psychiatry.
- A placebo-controlled study of sildenafil effects on cognition in Schizophrenia.
- Predictors of early abstinence in smokers with Schizophrenia.
- A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia.
- A prototype approach toward antipsychotic medication adherence in Schizophrenia.
- Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic Schizophrenia.
- Aripiprazole added to overweight and obese olanzapine-treated Schizophrenia patients.
- Dysfunction of a cortical midline network during emotional appraisals in Schizophrenia.
- Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with Schizophrenia treated with clozapine but not olanzapine.
- Modafinil for clozapine-treated Schizophrenia patients: a double-blind, placebo-controlled pilot trial.
- Fatigue in psychiatric HIV patients: a pilot study of psychological correlates.
- Clozapine use in HIV-infected Schizophrenia patients: a case-based discussion and review.
- Interferon-induced Psychosis as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion.
- Analysis of peripheral immune activation in Schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR).
- Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with Schizophrenia.
- Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with Schizophrenia on clozapine or risperidone.
- Assessing clinicians'' management of first episode Schizophrenia using clinical case vignettes.
Schools
Medical Faculty Mannheim at the University of Heidelberg
UmdNj
Mgh
Procedures Preformed
- Psychotherapy and Psychophysiological Therapy (incl. Biofeedback)
Conditions Treated
- Anxiety
- Bipolar Disorder
- Combination Drug Dependence
- Drug and Alcohol Dependence
- View All
Doctors Specialties
- Psychosomatic Medicine
- Psychiatry
Accepted Insurances
Awards
- Super Doctor
Education
-
UMDNJ-Robert Wood Johnson Medical School -
Ruprecht Karl University Faculty of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1710977038 | |
| NPPES Provider LastName | FREUDENREICH | |
| NPPES Provider FirstName | OLIVER | |
| NPPES Provider ZIPCode | 021142696 | |
| NPPES Provider State | MA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 1852.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710977038 |
| Last Name Of The Provider | FREUDENREICH |
| First Name Of The Provider | OLIVER |
| View All |
Similar Doctors
|
|
Dr. Ana Ivkovic, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos G. Fernandez Robles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Virginie-Anne Chouinard, MD |
|
|
Dr. Farah T. Rahiem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olga O. Hewett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hadine Joffe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane T. Schwartz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joyce E. Myers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leena P. Mittal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruta M. Nonacs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grace Chang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rozan A. Omdah, MD
This Doctor is OpenDoctor Recommended.
|